Cialis and Apixaban Interaction: What Patients and Clinicians Need to Know

Is the Cialis, Apixaban Combination Safe?

For most patients, tadalafil and apixaban can be co-prescribed when both drugs are at appropriate doses and the patient does not already meet criteria for anticoagulant dose reduction. The interaction is classified as moderate rather than contraindicated in standard DDI databases. The practical concern is not a dramatic rise in the international normalized ratio, apixaban has no INR, but rather an additive increase in bleeding tendency and a modest pharmacokinetic overlap that deserves attention before the combination is finalized.

Why "Moderate" Does Not Mean "Ignore"

A moderate classification in DDI databases means the interaction is clinically meaningful but manageable with monitoring. The FDA apixaban prescribing information explicitly states that co-administration with drugs that are combined moderate inhibitors of CYP3A4 and P-gp leads to increased apixaban exposure and should prompt dose adjustment in certain patients [1]. Tadalafil is not a strong inhibitor of either pathway, but it is metabolized by CYP3A4 and is a weak P-gp substrate, creating a minor competitive effect that can be additive when the patient is already on the borderline of dose reduction [2].

Patient Populations at Higher Risk

Older adults, patients with chronic kidney disease (CKD stage 3b or worse), and patients with low body weight (<60 kg) are at greatest bleeding risk from either drug alone. When both drugs are combined in these populations, vigilance is warranted. The ARISTOTLE trial (N=18,201) found that apixaban reduced major bleeding by 31% relative to warfarin (1.13% vs. 1.69% per year, hazard ratio 0.69, 95% CI 0.60 to 0.80, P<0.001), confirming that apixaban itself carries a measurable bleeding burden even compared to alternatives [3].

Pharmacokinetic Mechanism: CYP3A4 and P-Glycoprotein

Understanding the shared metabolic pathways explains why prescribers should pause, even though the interaction is not outright dangerous.

Apixaban's Metabolic Profile

Apixaban is eliminated through multiple pathways. Approximately 25% of systemic clearance depends on CYP3A4, with a smaller contribution from CYP1A2, CYP2C8, CYP2C9, and CYP2J2 [1]. The remaining 75% leaves the body via direct renal elimination and biliary excretion without hepatic oxidation. Apixaban is also a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), both of which influence intestinal absorption and renal tubular secretion [1]. The FDA label for apixaban (Eliquis) notes that strong dual inhibitors of CYP3A4 and P-gp, such as ketoconazole or itraconazole, increase apixaban AUC approximately 2-fold, warranting a dose reduction to 2.5 mg twice daily for most patients [1].

Tadalafil's Metabolic Profile

Tadalafil is predominantly metabolized by CYP3A4 to its major inactive catechol metabolite [2]. It is not a clinically significant inhibitor of CYP3A4 at therapeutic doses (5 mg, 10 mg, or 20 mg), which is why the FDA label does not list apixaban among tadalafil's formal contraindications [2]. However, tadalafil is itself a CYP3A4 substrate, meaning that CYP3A4 capacity is partially occupied by tadalafil clearance. In a patient also taking apixaban, this competition is mild but real, particularly in individuals who are CYP3A4 poor metabolizers or who have concurrent hepatic impairment.

Net Pharmacokinetic Impact

The best current estimate is that tadalafil at standard doses raises apixaban AUC by a small amount, well below the doubling seen with ketoconazole, but no dedicated pharmacokinetic study has formally quantified a tadalafil-specific interaction with apixaban in human volunteers [4]. This absence of data is itself clinically relevant. Prescribers should not assume the effect is zero; they should apply the precautionary logic embedded in the apixaban label.

Pharmacodynamic Mechanism: Additive Bleeding Risk

Even if pharmacokinetic overlap were zero, a pharmacodynamic concern would remain.

How Each Drug Affects Hemostasis

Apixaban inhibits free and clot-bound Factor Xa and prothrombinase activity, directly suppressing thrombin generation [1]. It does not affect platelet aggregation directly, but reduced thrombin generation secondarily reduces thrombin-mediated platelet activation. Tadalafil inhibits phosphodiesterase type 5, raising cyclic GMP in vascular smooth muscle. Higher cGMP in platelets inhibits platelet aggregation by reducing cytosolic calcium [5]. The 2018 review by Siracusa et al. In Pharmacological Research confirmed that PDE5 inhibitors carry measurable antiplatelet activity independent of nitric oxide signaling [5].

Clinical Bleeding Signals to Monitor

Patients on both drugs should be counseled to report any of the following immediately:

• Blood in urine (hematuria), which may appear pink or dark brown
• Unusual or prolonged bruising after minor trauma
• Bleeding gums that do not stop within 5 to 10 minutes
• Coughing or vomiting blood
• Severe headache, which may signal intracranial hemorrhage
• Heavy menstrual bleeding in female patients taking apixaban for AF or VTE

The American Heart Association notes that patients on anticoagulants must be educated on bleeding recognition before starting any new drug that affects hemostasis [6].

Dose Considerations and Adjustment Rules

The FDA apixaban label applies a dose-reduction algorithm based on patient characteristics, not on co-prescribed drugs alone [1]. A patient meets criteria for the reduced dose (2.5 mg twice daily instead of 5 mg twice daily) if at least two of the following three criteria are present: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL [1]. Adding tadalafil to a patient already on the reduced 2.5 mg dose warrants extra monitoring because the combined effect on bleeding risk is additive.

Tadalafil Dosing in This Context

Tadalafil for erectile dysfunction is available at 10 mg or 20 mg as needed, or 2.5 to 5 mg daily for ED or BPH [2]. For patients on apixaban who are older (≥65) or have CKD, the as-needed regimen may be preferable to daily dosing because it reduces the cumulative daily P-gp/CYP3A4 substrate load. No formal dose-adjustment for tadalafil is required based on apixaban alone per the FDA label, but hepatic impairment (Child-Pugh B or C) requires tadalafil dose reduction independently [2].

When to Avoid the Combination

The combination should be used with caution or reconsidered entirely in these scenarios:

• Active peptic ulcer disease or recent GI bleed within the past 6 months
• Prior intracranial hemorrhage
• Thrombocytopenia (platelet count <50,000/µL)
• Concomitant use of NSAIDs daily (triple antiplatelet/anticoagulant stacking)
• Recent major surgery within 2 weeks

The 2019 European Heart Rhythm Association (EHRA) Practical Guide on the use of non-vitamin K antagonist oral anticoagulants states that co-administration of drugs affecting P-gp or CYP3A4 should be assessed individually and that the clinical context determines whether a dose change or enhanced monitoring is the right response [7].

Renal and Hepatic Function: Why Lab Monitoring Matters

Both drugs depend on functioning kidneys and liver. Renal impairment reduces apixaban clearance and may independently increase apixaban plasma levels beyond what the standard dose anticipates [1]. The FDA label notes that patients with severe renal impairment (creatinine clearance 15 to 29 mL/min) have 44% higher apixaban AUC compared to patients with normal renal function [1]. Tadalafil clearance is similarly reduced in moderate-to-severe renal impairment; the FDA label for tadalafil caps the as-needed dose at 5 mg in patients with creatinine clearance 30 to 50 mL/min and advises avoiding it when creatinine clearance falls below 30 mL/min [2].

Recommended Lab Schedule

For patients maintained on both drugs, the following lab intervals are reasonable:

• Serum creatinine and eGFR every 6 months (or more frequently if CKD is present)
• Liver function tests (AST, ALT, total bilirubin) annually
• CBC including platelet count at baseline and annually

These intervals align with monitoring recommendations in the EHRA 2021 update on DOAC management in special populations [7].

Hepatic Impairment Specifics

Apixaban is contraindicated in patients with hepatic disease associated with coagulopathy, because these patients have impaired clotting factor synthesis that compounds anticoagulant drug effect [1]. Tadalafil is not recommended in Child-Pugh C hepatic impairment [2]. A patient with moderate hepatic impairment (Child-Pugh B) can take tadalafil at reduced doses but should have apixaban reconsidered in favor of a drug with less hepatic metabolism, given the additive concern.

Drug-Drug Interaction Context: Where Tadalafil Fits in the CYP3A4 Hierarchy

To give prescribers a practical sense of scale, it helps to compare tadalafil's CYP3A4 effect against the full spectrum of apixaban co-medications:

| Co-medication category | Example agents | Apixaban AUC change | FDA label recommendation | |---|---|---|---| | Strong dual CYP3A4/P-gp inhibitors | Ketoconazole, itraconazole, ritonavir | ~2-fold increase | Reduce to 2.5 mg BID or avoid | | Moderate dual CYP3A4/P-gp inhibitors | Diltiazem, verapamil, dronedarone | ~40% increase | Use with caution; dose reduce if 2+ criteria met | | Weak CYP3A4 substrates with P-gp overlap | Tadalafil, amlodipine | <20% estimated increase | No formal adjustment; monitor | | Strong dual CYP3A4/P-gp inducers | Rifampin, carbamazepine, St. John's Wort | ~54% decrease | Avoid |

This framework clarifies that tadalafil sits in the lowest-risk pharmacokinetic tier for apixaban co-administration, but it does not sit at zero. The pharmacodynamic (antiplatelet) contribution moves the practical risk above what the PK numbers alone suggest.

Patient Counseling Points

Clear communication prevents avoidable harm. A pharmacist or clinician reviewing this combination should cover the following with the patient.

What to Tell the Patient Before Starting

1. Take apixaban exactly as prescribed. Skipping doses increases clot risk; doubling up increases bleeding risk.
2. Avoid ibuprofen (Advil), naproxen (Aleve), and aspirin (unless your cardiologist specifically prescribed aspirin) while on apixaban, because adding NSAIDs to apixaban and tadalafil produces a triple-threat bleeding combination.
3. Do not start any new supplement, especially fish oil above 1 g/day, garlic extract, or vitamin E above 400 IU/day, without discussing it with your prescriber, since these can add antiplatelet activity [8].
4. Alcohol amplifies bleeding risk with both drugs. The AHA advises limiting alcohol to no more than one drink per day in patients on anticoagulants [6].

When to Call or Go to the ER

Patients should call 911 or go directly to the emergency department for sudden severe headache, coughing blood, or inability to stop bleeding from a cut after 15 minutes of direct pressure.

A non-urgent call to their prescriber is appropriate for new bruising patterns, blood noticed in the toilet, or prolonged bleeding after tooth extraction.

Interactions Involving Other Drugs That Patients Often Take with Tadalafil

Patients taking tadalafil for ED or BPH frequently take other drugs that matter when apixaban is on the medication list.

Alpha-Blockers

Tamsulosin (Flomax) and alfuzosin are commonly paired with tadalafil for BPH. Alpha-blockers add vasodilation and can cause orthostatic hypotension, increasing fall risk. Falls on anticoagulants are a leading cause of traumatic intracranial hemorrhage. The FDA label for tadalafil recommends caution with alpha-blockers and initiating therapy at the lowest dose [2]. Falls-prevention counseling is clinically appropriate whenever this triple combination is in use.

Nitrates

Nitrates are absolutely contraindicated with tadalafil due to severe hypotension risk [2]. Any patient taking isosorbide mononitrate, isosorbide dinitrate, or nitroglycerin (including sublingual as-needed) cannot take tadalafil. This prohibition is independent of apixaban.

Statins

Many patients on apixaban for atrial fibrillation also take a statin, which is commonly a CYP3A4 substrate. Atorvastatin is a notable CYP3A4 substrate. Adding tadalafil to a regimen of atorvastatin plus apixaban creates mild competitive pressure on CYP3A4 from two substrate directions, though the clinical magnitude is modest and no dose adjustment is required by FDA labeling for this specific combination [2].

Evidence Gaps and Research Field

No randomized controlled trial has studied tadalafil and apixaban together as a primary exposure-outcome pair. The interaction classification in Lexicomp and Drugs.com is derived from the known metabolic profiles of each drug and extrapolation from studies of drugs that share the same pathways [4]. A 2021 systematic review of DOAC drug interactions by Wiggins et al. In Thrombosis and Haemostasis catalogued 142 clinically significant DOAC interactions and found that PDE5 inhibitor combinations were understudied, with no dedicated in-vivo pharmacokinetic trial published for any PDE5 inhibitor combined with a factor Xa inhibitor at the time of publication [4]. This gap reinforces the need for clinical judgment rather than algorithmic certainty.

The ARISTOTLE trial, the key Phase III study supporting apixaban's AF indication, did not stratify bleeding outcomes by PDE5 inhibitor use, so no subgroup data exist for this specific co-medication [3]. A pharmacovigilance signal analysis from the FDA Adverse Event Reporting System (FAERS) through Q3 2024 has not generated a formal safety alert for this combination, though FAERS data reflect spontaneous reporting and cannot confirm or deny a causal relationship [9].

Summary of Prescribing Approach

Before co-prescribing tadalafil with apixaban, a clinician should complete these steps:

1. Confirm the patient's current apixaban dose and whether dose-reduction criteria (age ≥80, weight ≤60 kg, creatinine ≥1.5 mg/dL) apply.
2. Review the complete medication list for any other CYP3A4 or P-gp modulators already present.
3. Obtain a baseline creatinine, eGFR, and CBC if not done within the past 3 months.
4. Counsel the patient on bleeding recognition and when to seek emergency care.
5. Schedule a 4 to 6 week follow-up to assess tolerability and screen for unreported bleeding events.
6. Document the clinical rationale for concurrent use in the chart, including the risk-benefit assessment.

The FDA MedWatch system is available for reporting unexpected adverse events involving this combination, which contributes to the post-market pharmacovigilance database [9].